Stockscreener 앱 받기
5.215
3.06%
0.155
시간 외 거래:
5.22
0.005
+0.10%
전일 마감가:
$5.06
열려 있는:
$5
하루 거래량:
458.90K
Relative Volume:
0.31
시가총액:
$337.40M
수익:
$500
순이익/손실:
$-54.44M
주가수익비율:
-4.4733
EPS:
-1.1658
순현금흐름:
$-49.91M
1주 성능:
+15.12%
1개월 성능:
+12.39%
6개월 성능:
+1.86%
1년 성능:
+38.70%
1일 변동 폭
$4.99
$5.27
1주일 범위
$4.55
$5.27
52주 변동 폭
$3.25
$10.08
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.215 | 327.37M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | Leerink Partners | Outperform |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering Stock Price Forecast. Should You Buy IMRX? - StockInvest.us
HC Wainwright Estimates Immuneering Q3 Earnings - MarketBeat
Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright - MarketBeat
Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
H.C. Wainwright initiates Immuneering stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Immuneering stock coverage with buy rating By Investing.com - Investing.com India
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Immuneering (NASDAQ:IMRX) Releases Earnings Results - MarketBeat
Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
Immuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView
Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - quiverquant.com
Immuneering Corporation Q2 Net Income USD -17 - moomoo.com
Immuneering reports strong pancreatic cancer tr... - Pluang
IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Income Statement - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
IMRX|Immuneering Corp|Price:4.355|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX) Cash Flow - TradingKey
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immuneering reports preclinical data on atebimetinib in journal - Investing.com
IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus
Immuneering (NASDAQ:IMRX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Immuneering Corporation Announces Grants of Inducement Awards - The Manila Times
Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
Immuneering (IMRX) awards CFO Andrew Gengos 650,000 stock options - Stock Titan
Immuneering Corporation Announces Inducement Equity Grants to New CFO and Employee - Quiver Quantitative
Immuneering’s New CFO Gets 650,000-Share Option With $4.78 Exercise Price - Stock Titan
Immuneering Corp (IMRX) CFO discloses 225,000 Class A shares - Stock Titan
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com
If You Invested $1,000 in Immuneering Corp (IMRX) - Stock Titan
IMRXImmuneering Corp Latest SEC Filings - Finviz
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - Sahm
Immuneering Corporation (IMRX) Surges 5% as Stock Approaches Key Resistance LevelBull Pennant - dars.gov.et
Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX) - TradingView
IMRX Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Immuneering Corp For: 24 June By Investing.com - Investing.com Nigeria
Immuneering CEO Zeskind buys $10,948 in stock - Investing.com UK
Immuneering CEO Zeskind buys $10,948 in stock By Investing.com - Investing.com India
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immuneering Corp 주식 (IMRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 15 '26 |
Buy |
4.15 |
6,035 |
25,045 |
382,531 |
| Brakewood Harold Eugene | Chief Business Officer |
Jan 16 '26 |
Buy |
4.76 |
5,250 |
24,990 |
11,050 |
| Schall Thomas J. | Director |
Jan 15 '26 |
Buy |
4.67 |
21,645 |
101,041 |
74,530 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jan 15 '26 |
Buy |
4.57 |
2,298 |
10,502 |
376,496 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jan 13 '26 |
Buy |
4.15 |
2,626 |
10,906 |
25,970 |
| Feinberg Peter | Director |
Jan 12 '26 |
Buy |
4.35 |
20,000 |
86,904 |
135,441 |
| Feinberg Peter | Director |
Oct 03 '25 |
Buy |
6.67 |
7,500 |
50,025 |
156,766 |
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
2.67%
0.04%
자본화:
|
볼륨(24시간):